Proteostasis Announces Formation of Independent Steering Committee of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for PTI-428 in Cystic Fibrosis

Author's Avatar
May 08, 2018
Article's Main Image

Program to Pursue Broad Label for PTI-428 as an Add-On Therapy to CFTR Modulator Based Treatment

PR Newswire